Key Points
- Noah Goodman sold 8,264 shares of Kymera (NASDAQ:KYMR) on April 9 at an average price of $87.50 for proceeds of $723,100 under a pre-arranged Rule 10b5‑1 plan to cover tax withholding, trimming his stake by 13.37% to 53,542 shares.
- Kymera missed Q4 estimates, reporting ($0.97) EPS vs. ($0.77) expected and revenue of $2.87M (down 60.8% YoY), leaving the company with very negative margins and a market cap around $6.94 billion.
- Major institutional investors (e.g., Baker Bros., Avoro, Price T. Rowe, Vanguard) have been increasing positions, and analysts' consensus is a Moderate Buy with an average target price near $118.90.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) insider Noah Goodman sold 2,000 shares of the stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $87.35, for a total value of $174,700.00. Following the transaction, the insider directly owned 51,542 shares of the company's stock, valued at approximately $4,502,193.70. This trade represents a 3.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Noah Goodman also recently made the following trade(s):
- On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.50, for a total value of $723,100.00.
Kymera Therapeutics Trading Down 2.6%
Shares of KYMR stock opened at $85.05 on Friday. The company has a market cap of $6.94 billion, a price-to-earnings ratio of -23.11 and a beta of 2.28. The stock has a 50 day simple moving average of $82.95 and a 200-day simple moving average of $73.26. Kymera Therapeutics, Inc. has a 12-month low of $22.05 and a 12-month high of $103.00.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.20). The business had revenue of $2.87 million for the quarter, compared to analysts' expectations of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The business's quarterly revenue was down 60.8% on a year-over-year basis. During the same period last year, the company posted ($0.88) earnings per share. On average, equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on the company. Citigroup increased their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a "buy" rating in a research note on Monday, March 2nd. Jefferies Financial Group assumed coverage on Kymera Therapeutics in a report on Monday, March 16th. They issued a "buy" rating and a $110.00 price target on the stock. UBS Group upped their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a "buy" rating in a report on Tuesday, March 3rd. Barclays upped their price target on Kymera Therapeutics to $133.00 and gave the stock an "overweight" rating in a report on Tuesday, January 27th. Finally, Stephens upped their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an "overweight" rating in a report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $118.90.
View Our Latest Report on KYMR
Institutional Investors Weigh In On Kymera Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC grew its holdings in Kymera Therapeutics by 169.1% during the 4th quarter. SG Americas Securities LLC now owns 22,693 shares of the company's stock valued at $1,766,000 after buying an additional 14,261 shares during the last quarter. Federated Hermes Inc. acquired a new stake in Kymera Therapeutics during the 3rd quarter valued at $31,622,000. Hudson Bay Capital Management LP grew its holdings in Kymera Therapeutics by 362.7% during the 3rd quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company's stock valued at $1,309,000 after buying an additional 18,134 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Kymera Therapeutics by 77.2% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company's stock valued at $1,007,000 after buying an additional 10,052 shares during the last quarter. Finally, Candriam S.C.A. grew its holdings in Kymera Therapeutics by 24.4% during the 3rd quarter. Candriam S.C.A. now owns 191,639 shares of the company's stock valued at $10,847,000 after buying an additional 37,536 shares during the last quarter.
About Kymera Therapeutics
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
